Chemomab Therapeutics (CMMB)

• Market cap: $30.9M
• 1 day: -2.38%
• 5 days: 1.86%
• 1 month: 0.61%
• 3 months: 3.80%
• 6 months: 64.20%
• Year to date: 204.95%
• 1 year: 221.57%
• 5 years: -97.22%
• 10 years: -97.22%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Employees: 20

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

192% more capital invested

Capital invested by funds: $2.45M [Q2] → $7.14M (+$4.69M) [Q3]

0.64% more ownership

Funds ownership: 0.94% [Q2] → 1.58% (+0.64%) [Q3]

0% more funds holding

Funds holding: 15 [Q2] → 15 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 571% upside
• Avg. target: $11 571% upside
• High target: $11 571% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target

571% upside $11

Outperform Reiterated

15 Nov 2024